HRP20210179T1 - Farmaceutski pripravak za modificirano otpuštanje - Google Patents
Farmaceutski pripravak za modificirano otpuštanje Download PDFInfo
- Publication number
- HRP20210179T1 HRP20210179T1 HRP20210179TT HRP20210179T HRP20210179T1 HR P20210179 T1 HRP20210179 T1 HR P20210179T1 HR P20210179T T HRP20210179T T HR P20210179TT HR P20210179 T HRP20210179 T HR P20210179T HR P20210179 T1 HRP20210179 T1 HR P20210179T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- modified release
- release according
- amount
- additive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10133808P | 2008-09-30 | 2008-09-30 | |
| EP09817723.1A EP2345410B1 (en) | 2008-09-30 | 2009-09-28 | Pharmaceutical composition for modified release |
| PCT/JP2009/066742 WO2010038690A1 (ja) | 2008-09-30 | 2009-09-28 | 放出制御医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210179T1 true HRP20210179T1 (hr) | 2021-05-28 |
Family
ID=42073454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210179TT HRP20210179T1 (hr) | 2008-09-30 | 2009-09-28 | Farmaceutski pripravak za modificirano otpuštanje |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20160184275A2 (enExample) |
| EP (2) | EP3827826A1 (enExample) |
| JP (2) | JP4688089B2 (enExample) |
| KR (1) | KR101524164B1 (enExample) |
| CN (2) | CN105232448A (enExample) |
| AU (1) | AU2009300752C1 (enExample) |
| BR (1) | BRPI0919466B1 (enExample) |
| CA (1) | CA2740342C (enExample) |
| CY (1) | CY1123724T1 (enExample) |
| DK (1) | DK2345410T3 (enExample) |
| ES (1) | ES2847876T3 (enExample) |
| HK (1) | HK1216232A1 (enExample) |
| HR (1) | HRP20210179T1 (enExample) |
| HU (1) | HUE052874T2 (enExample) |
| IL (1) | IL212033A (enExample) |
| LT (1) | LT2345410T (enExample) |
| MX (1) | MX351855B (enExample) |
| PL (1) | PL2345410T3 (enExample) |
| PT (1) | PT2345410T (enExample) |
| RU (1) | RU2495666C2 (enExample) |
| SI (1) | SI2345410T1 (enExample) |
| TW (1) | TWI478712B (enExample) |
| WO (1) | WO2010038690A1 (enExample) |
| ZA (1) | ZA201102406B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100355130B1 (ko) * | 1992-09-18 | 2003-01-30 | 야마노우치세이야쿠 가부시키가이샤 | 하이드로겔서방성정제 |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| JP5849946B2 (ja) * | 2010-03-29 | 2016-02-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| ES2665467T3 (es) * | 2010-03-29 | 2018-04-25 | Astellas Pharma Inc. | Composición farmacéutica de liberación modificada |
| KR20180118801A (ko) * | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| AP2014007645A0 (en) | 2011-10-21 | 2014-05-31 | Takeda Pharmaceutical | Sustained-release preparation |
| JP6123795B2 (ja) * | 2012-03-30 | 2017-05-10 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| EP2832730A4 (en) | 2012-03-30 | 2015-09-09 | Astellas Pharma Inc | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION |
| TW201424772A (zh) | 2012-08-31 | 2014-07-01 | Astellas Pharma Inc | 經口投與用醫藥組成物 |
| JP2017078023A (ja) * | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| CN104523635B (zh) * | 2014-12-23 | 2017-05-03 | 深圳万乐药业有限公司 | 米拉贝隆缓释药物组合物 |
| JP2018090490A (ja) | 2015-03-31 | 2018-06-14 | アステラス製薬株式会社 | ミラベグロン含有医薬組成物 |
| JP6618736B2 (ja) * | 2015-09-01 | 2019-12-11 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
| EP3448366A1 (en) * | 2016-04-25 | 2019-03-06 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| WO2017186593A1 (en) | 2016-04-25 | 2017-11-02 | Synthon B.V. | Tablets comprising mirabegron and solifenacin |
| EP3360866B1 (en) | 2017-02-14 | 2019-01-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Mirabegron prodrugs |
| KR102051132B1 (ko) * | 2017-03-17 | 2019-12-02 | 주식회사 종근당 | 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물 |
| KR20170088783A (ko) * | 2017-07-07 | 2017-08-02 | 지엘팜텍주식회사 | 미라베그론의 습식과립 조성물 |
| WO2019013583A2 (ko) | 2017-07-14 | 2019-01-17 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
| KR101937713B1 (ko) * | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
| US10478399B2 (en) * | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| CA3078568A1 (en) * | 2017-10-12 | 2019-04-18 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| EP3292864A1 (en) * | 2017-10-12 | 2018-03-14 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| KR20190089758A (ko) | 2018-01-22 | 2019-07-31 | (주)동구바이오제약 | 미라베그론 또는 이의 약제학적으로 허용가능한 염을 함유하는 지속 방출 제제 |
| KR102371567B1 (ko) | 2018-04-06 | 2022-03-07 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약학적 조성물 |
| KR102659760B1 (ko) | 2018-10-18 | 2024-04-23 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약제학적 조성물 |
| KR102062791B1 (ko) | 2019-02-26 | 2020-01-06 | 신일제약 주식회사 | 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제 |
| KR102897443B1 (ko) | 2019-06-28 | 2025-12-08 | 한미약품 주식회사 | 제어 방출형 미라베그론 제제 및 이의 제조방법 |
| JP7377782B2 (ja) * | 2019-09-04 | 2023-11-10 | 信越化学工業株式会社 | フィルム成形用組成物及びフィルム |
| AR121207A1 (es) * | 2020-01-31 | 2022-04-27 | Nippon Shinyaku Co Ltd | Composición de liberación controlada |
| KR102546923B1 (ko) * | 2020-03-03 | 2023-06-26 | 동광제약 주식회사 | 미라베그론을 포함하는 제어 방출 제제 |
| CN113662922A (zh) * | 2020-10-29 | 2021-11-19 | 北京莱瑞森医药科技有限公司 | 一种米拉贝隆缓释组合物及其制备方法和应用 |
| JP7904682B2 (ja) * | 2021-10-28 | 2026-08-13 | 東和薬品株式会社 | 放出制御医薬組成物 |
| CN114306262B (zh) * | 2021-12-30 | 2023-09-05 | 乐泰药业有限公司 | 米拉贝隆缓释片及其制备方法和质量检测方法 |
| EP4338729A1 (en) * | 2022-09-19 | 2024-03-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet comprising mirabegron |
| JP7820861B2 (ja) * | 2024-01-26 | 2026-02-26 | 富士化学工業株式会社 | 徐放性製剤 |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
| WO2025263523A1 (ja) * | 2024-06-21 | 2025-12-26 | 沢井製薬株式会社 | ミラベグロン含有製剤 |
| WO2026064392A1 (en) | 2024-09-17 | 2026-03-26 | Flavostar Llc | Fixed dose combination of flavoxate and beta-3 adrenergic receptor agonists, and formulations and manufacturing processes thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| JPH03145418A (ja) | 1989-10-27 | 1991-06-20 | Sumitomo Pharmaceut Co Ltd | 塩基性薬物塩酸塩の徐放性製剤 |
| GB9111426D0 (en) | 1991-05-28 | 1991-07-17 | Ici Plc | Chemical compounds |
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| KR100355130B1 (ko) * | 1992-09-18 | 2003-01-30 | 야마노우치세이야쿠 가부시키가이샤 | 하이드로겔서방성정제 |
| SK279684B6 (sk) | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tableta a spôsob jej výroby |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| DE69524214T3 (de) | 1994-05-06 | 2008-05-15 | Pfizer Inc. | Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe |
| GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| PT1014941E (pt) | 1996-06-26 | 2009-07-08 | Univ Texas | Formulação farmacêutica extrudível por termofusão |
| EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| CA2263659A1 (en) | 1996-08-19 | 1998-02-26 | Kissei Pharmaceutical Co., Ltd. | Preventive/remedy for frequent urination and urinary incontinence |
| CA2302496C (en) | 1997-08-28 | 2009-12-08 | Mount Cook Biosciences, Inc. | Urinary incontinence therapy |
| KR100506568B1 (ko) | 1997-10-17 | 2006-04-21 | 아스텔라스세이야쿠 가부시키가이샤 | 아미드유도체및이의염,및이를포함하는약제학적제제 |
| ATE250570T1 (de) | 1997-12-18 | 2003-10-15 | Kissei Pharmaceutical | Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| ATE275126T1 (de) | 1998-04-14 | 2004-09-15 | Kissei Pharmaceutical | 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| MY126489A (en) | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
| DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| ES2262528T3 (es) | 1999-08-04 | 2006-12-01 | Astellas Pharma Inc. | Composiciones medicinales estables para administracion oral que utilizan oxidos de hierro. |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| GB2356197A (en) | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| JP2001114736A (ja) | 1999-10-19 | 2001-04-24 | Kissei Pharmaceut Co Ltd | ２−アミノプロパノール誘導体 |
| US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US6419954B1 (en) | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| US6368628B1 (en) | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| WO2002032897A1 (en) | 2000-10-20 | 2002-04-25 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| GB0117618D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| US20030072802A1 (en) | 2001-10-11 | 2003-04-17 | R.T. Alamo Ventures, Inc. | Sustained release topiramate |
| US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| WO2003039530A1 (en) | 2001-11-07 | 2003-05-15 | Synthon B.V. | Tamsulosin tablets |
| IL162293A0 (en) * | 2001-12-19 | 2005-11-20 | Alza Corp | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| DE60323964D1 (de) | 2002-04-29 | 2008-11-20 | Alza Corp | Poly(alkylenoxide) von reduziertem format mit reboxetin zur verringerung der bildung von verunreinigungen |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| CA2503570C (en) * | 2002-11-07 | 2011-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| KR100742001B1 (ko) | 2003-03-21 | 2007-07-23 | 다이노젠 파마세우티컬스, 인코포레이티드 | 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법 |
| SI1631251T1 (sl) | 2003-04-24 | 2011-10-28 | Jagotec Ag | Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra |
| US20050042289A1 (en) | 2003-04-29 | 2005-02-24 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophylic and other active agents |
| US7994214B2 (en) | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
| DE602004030931D1 (enExample) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| DE10352132A1 (de) | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
| US8128958B2 (en) * | 2003-11-10 | 2012-03-06 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
| JP2005162737A (ja) | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
| US8197846B2 (en) | 2003-11-10 | 2012-06-12 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
| JP2005162736A (ja) | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| KR20080083068A (ko) | 2004-05-24 | 2008-09-12 | 더 프록터 앤드 갬블 캄파니 | 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태 |
| WO2006009769A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| US20050287185A1 (en) | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
| US20080095841A1 (en) | 2004-10-06 | 2008-04-24 | Eisai R&D Management Co., Ltd. | Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| BRPI0608573A2 (pt) * | 2005-03-08 | 2017-07-25 | Lifecycle Pharma As | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. |
| EP1769792A1 (de) | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| US20100172988A1 (en) | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008084698A1 (ja) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | タクロリムス徐放性医薬組成物 |
| US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| WO2009052353A2 (en) | 2007-10-17 | 2009-04-23 | Dr. Reddy's Laboratories Ltd. | Trospium pharmaceutical formulations |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| ES2665467T3 (es) | 2010-03-29 | 2018-04-25 | Astellas Pharma Inc. | Composición farmacéutica de liberación modificada |
| JP5849946B2 (ja) | 2010-03-29 | 2016-02-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| US8898159B2 (en) | 2010-09-28 | 2014-11-25 | International Business Machines Corporation | Providing answers to questions using logical synthesis of candidate answers |
-
2009
- 2009-09-25 TW TW098132502A patent/TWI478712B/zh active
- 2009-09-28 ES ES09817723T patent/ES2847876T3/es active Active
- 2009-09-28 US US12/568,313 patent/US20160184275A2/en not_active Abandoned
- 2009-09-28 EP EP20212426.9A patent/EP3827826A1/en active Pending
- 2009-09-28 WO PCT/JP2009/066742 patent/WO2010038690A1/ja not_active Ceased
- 2009-09-28 RU RU2011117274/15A patent/RU2495666C2/ru active
- 2009-09-28 HR HRP20210179TT patent/HRP20210179T1/hr unknown
- 2009-09-28 EP EP09817723.1A patent/EP2345410B1/en not_active Revoked
- 2009-09-28 LT LTEP09817723.1T patent/LT2345410T/lt unknown
- 2009-09-28 CN CN201510642287.2A patent/CN105232448A/zh active Pending
- 2009-09-28 MX MX2011003445A patent/MX351855B/es active IP Right Grant
- 2009-09-28 PT PT98177231T patent/PT2345410T/pt unknown
- 2009-09-28 HU HUE09817723A patent/HUE052874T2/hu unknown
- 2009-09-28 SI SI200932110T patent/SI2345410T1/sl unknown
- 2009-09-28 DK DK09817723.1T patent/DK2345410T3/da active
- 2009-09-28 JP JP2010531838A patent/JP4688089B2/ja active Active
- 2009-09-28 BR BRPI0919466-5A patent/BRPI0919466B1/pt not_active IP Right Cessation
- 2009-09-28 CN CN2009801386919A patent/CN102170878A/zh active Pending
- 2009-09-28 CA CA2740342A patent/CA2740342C/en active Active
- 2009-09-28 AU AU2009300752A patent/AU2009300752C1/en active Active
- 2009-09-28 PL PL09817723T patent/PL2345410T3/pl unknown
- 2009-09-28 KR KR1020117009897A patent/KR101524164B1/ko active Active
-
2010
- 2010-12-13 JP JP2010276634A patent/JP5625855B2/ja active Active
-
2011
- 2011-03-30 IL IL212033A patent/IL212033A/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02406A patent/ZA201102406B/en unknown
-
2016
- 2016-04-13 HK HK16104217.1A patent/HK1216232A1/zh unknown
-
2017
- 2017-02-14 US US15/432,854 patent/US10842780B2/en active Active
-
2020
- 2020-11-19 US US16/952,795 patent/US20210322387A1/en not_active Abandoned
-
2021
- 2021-01-18 CY CY20211100034T patent/CY1123724T1/el unknown
-
2024
- 2024-03-22 US US18/613,270 patent/US12059409B1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011079859A5 (enExample) | ||
| RU2011117274A (ru) | Фармацевтическая композиция для модифицированного высвобождения | |
| NZ596657A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
| JP5489471B2 (ja) | Ｐｅｇ充填硬質カプセル剤のバンドシール | |
| ES2324909T3 (es) | Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion. | |
| SI2659881T1 (en) | Formulation of the delayed release medicinal product | |
| US9636376B2 (en) | Stable compositions of peptide epoxy ketones | |
| RU2011136636A (ru) | Фармацевтическая композиция для орального введения | |
| JP2010265321A5 (enExample) | ||
| ES2832699T3 (es) | Cápsulas recubiertas de liberación modificada | |
| WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
| PE20080423A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| EP1312366A8 (en) | Aqueous pharmaceutical compositions | |
| WO2015082562A1 (en) | Process for the production of drug formulations for oral administration | |
| JP2020510660A5 (enExample) | ||
| MX2013001637A (es) | Composiciones farmaceuticas de liberacion controlada oral de blonanserina. | |
| HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
| PH12017501831A1 (en) | Pharmaceutical compositions for oral administration | |
| RU2019109695A (ru) | Лекарственная форма для пролонгированного ослабления симптомов | |
| EP3187170A1 (en) | Pharmaceutical soft gelatin capsule dosage form with modified guar gum | |
| WO2007100822A3 (en) | Fluvastatin sodium pharmaceutical compositions | |
| US8962687B2 (en) | Method of treating liver disorders | |
| CO6160302A2 (es) | Formulaciones farmaceuticas | |
| JP5420877B2 (ja) | 眼科用剤 | |
| PL214226B1 (pl) | Preparat zawierajacy podstawione pochodne imidazolu |